Pages

Monday, 14 June 2010

NHS Choice guidance on taking Statins

Considerations

When to avoid statins

Statins should not be taken if you have:
  • liver disease
  • persistently abnormal liver function blood tests
Before you start taking a statin, your doctor should ensure your liver function is normal. This involves carrying out a blood test to check for the liver enzyme (substance in the blood) serum transaminase.
This should be repeated one to three months after you start taking the statin and at six-month to one-year intervals while you are taking it. If the amount of serum transaminase in your blood rises to and stays at three times the upper limit of normal, your doctor will advise you to stop taking the statin.


Using statins with caution

Statins should be taken with caution if you have risk factors for developing the rare side effects of myopathy and rhabdomyolysis (types of muscle disorder that cause muscle pain and breakdown of muscle tissue). These risk factors include:
  • being over 70 years old
  • having a history of liver disease
  • drinking large quantities of alcohol
  • having a history of muscle side effects when taking a statin or fibrate (another type of medicine for high cholesterol)
  • having a family history of myopathy (muscle damage) or rhabdomyolysis (kidney damage caused by a substance called myoglobin that is released into the blood when your muscles are inflamed or damaged)
If you have an underactive thyroid, only take a statin if your thyroid problem is being treated and is under control.

Side Effects

Muscle effects

Statins can occasionally cause inflammation (swelling) and damage to your muscles. Speak to your doctor if you experience muscle pain, tenderness or weakness that cannot be explained (for example, not due to physical work).
Your doctor will carry out a blood test to measure a substance in your blood called creatinine kinase (CK), which is released into the blood when your muscles are inflamed or damaged. If the level of CK in your blood is more than five times the normal level, your doctor will advise you to stop taking the statin. Once your CK level has returned to normal, your doctor may suggest you start taking the statin again, but at a lower dose.

Common side effects

Up to 1 in 10 people may experience the following:
  • gastrointestinal disorders, such as constipation, diarrhoea, dyspepsia (acid in the stomach) and flatulence (passing wind)
  • headache
  • insomnia (difficulty sleeping)
  • myalgia (pain in the muscles) and arthralgia (pain in the joints)
  • nausea (feeling sick)

Less common side effects

Up to 1 in 100 people may experience the following:
  • loss of appetite
  • myopathy (muscle damage)
  • peripheral neuropathy (loss of sensation or pain in the nerve endings of the hands and feet)
  • skin rash
  • vomiting (being sick)

Rare and very rare side effects

Between 1 in 1,000 and 1 in 10,000 people may experience the following:
  • dizziness
  • hepatitis (inflammation of the liver)
  • rhabdomyolysis, kidney damage caused by a substance caused myoglobin, which is released into the blood when a muscle is severely inflamed and damaged

Ability to drive

Statins are unlikely to affect your ability to drive. However, they may occasionally cause dizziness. If this affects you, do not drive.

Interactions with other Medicines

Interactions with food and Grapefruit Juice

  • Avoid drinking grapefruit juice if you are taking simvastatin. Grapefruit juice reduces the breakdown by the liver of simvastatin, which raises the level of simvastatin in the blood and makes you more likely to get side effects.
  • Atorvastatin interacts with grapefruit juice if you drink large quantities, but an occasional glass is thought to be safe. It is safe to drink grapefruit juice if you are taking any of the other statins.


Thursday, 13 May 2010

Bowel screening 'revolution' could slash cancer rate

reposted from: http://www.newscientist.com/article/dn18840-bowel-screening-revolution-could-slash-cancer-rate.html?DCMP=OTC-rss&nsref=health

13:42 29 April 2010 by Jessica Griggs

Epidemiologist Wendy Atkin from Imperial College London explains how a revolution in bowel cancer screening could drastically cut the death rate.
How does this screening work?
It involves examining the lower third of the bowel, where more than half of bowel cancers are located. A nurse looks inside the bowel using a flexible instrument with a camera on the end called a sigmoidoscope, or Flexi-Scope. This transmits an image onto a TV monitor so we can examine the surface of the bowel wall for polyps – clusters of cells that can become cancerous over the course of someone's life. These can be removed by threading a kind of lasso down the Flexi-Scope and pinching them off. It's a painless procedure and can be done in about 5 minutes. Removing these polyps through the Flexi-Scope prevents them from turning into cancers.
How does this compare with current screening?
We [currently] use a faecal occult blood test (FOBT), which involves looking for traces of blood in your stool at home. This could be a sign of very early cancer. If it is positive, you have a colonoscopy to find the source of the bleeding. A colonoscope is like a longer version of the Flexi-Scope but it can examine all around the bowel.
The big difference between the FOBT and the Flexi-Scope is that the stool test detects the early cancer but doesn't find the polyps, so it can't prevent the disease and cut the number of new cases of bowel cancer.
How do you know how effective the test is?
It is already used in the US, but in the UK we've just completed the first randomised trial with 170,000 people aged 54 to 65 – the age at which most people prone to polyps will have developed them. 
Having the test reduced the risk of getting the disease throughout the whole bowel by a third and the risk of dying from bowel cancer by more than 40 per cent, compared with 25 per cent for the FOBT.
And one of the best things is that you only need to take the Flexi-Scope test once?
That's what the result show so far – after 11 years there was no sign of the polyps recurring. We will follow the trial group for the rest of their lives to see whether one test really is enough.
Back in 1994, we came up with a theory that most bowel cancers arise from polyps, and most polyps in the lower bowel develop by the time you're 60. So if you examine the bowel just before someone is 60, then you should be able to classify them as having polyps, and remove them – or not having polyps, and therefore not destined to get them because they would have already done so.
Would this screening replace FOBT? And what about genetic cancer?
You would have the Flexi-Scope exam in your 50s and follow that up with the FOBT in your 60s, thereby ensuring you were screened for cancer in both upper and lower bowel.
Someone with a genetic risk is likely to be at increased risk of developing polyps. But if there is a strong family history, suggesting genetic risk, it might be better to have regular colonoscopy.
Will the test be accepted as part of the UK's National Health Service screening programme?
Having proven that it works, it's now down to the economic analysis but we have already worked out that for every person screened, the NHS saves £28 on potential treatment costs.
Journal reference: The Lancet, DOI: 10.1016/s0140-6736(10)60551-x (in press)

    Monday, 8 February 2010

    Genes reveal 'biological ageing'

    Telomeres at the end of chromosomes shorten with age

    Gene variants that might show how fast people's bodies are actually ageing have been pinpointed by scientists.
    Researchers from the University of Leicester and Kings College London say the finding could help spot people at higher risk of age-related illnesses.

    People carrying the variant had differences in the "biological clock" within all their cells.

    The British Heart Foundation said the findings could offer a clue to ways of preventing heart disease.
    While doctors know that as people age they are more at risk from diseases such as Alzheimer's, Parkinson's and heart disease, some people fall prey to these at an earlier age than expected.

    Telomeres
    One theory suggests that biological timers called "telomeres", part of the chromosomes in every cell that carry genetic code, may be a factor in this.

    What our study suggests is that some people are genetically programmed to age at a faster rate
    Professor Tim Spector, King's College London

    From birth, every time a cell divides, the telomeres get shorter and there is some evidence that people with shorter telomeres, either because they diminish more quickly or because they were born with shorter versions, may be at higher risk from age-related illness.

    The researchers say in the journal, Nature Genetics, that they looked at more than 500,000 genetic variations across the entire human genome to see which variants cropped up more frequently in people known to have shorter telomeres.

    They eventually located a number of variants located near a gene called TERC which, in people carrying them, seemed to be equivalent to an extra three or four years of "biological ageing".

    Bad lifestyles
    Professor Tim Spector, from King's College London, said: "What our study suggests is that some people are genetically programmed to age at a faster rate.

    "Alternatively, genetically susceptible people may age even faster when exposed to proven 'bad' environments for telomeres such as smoking, obesity or lack of exercise - and end up several years biologically older or succumbing to more age-related diseases."

    Professor Jeremy Pearson, associate medical director at the British Heart Foundation, which part-funded the study, said it was not yet clear whether telomeres did contribute to an increased risk of disease.

    He said: "Understanding how our cells age is an important step in our quest for better ways to prevent and treat heart disease.

    "Perhaps in the future one of the ways we try to reduce the risk of, or treat, heart disease would be to use an 'anti-ageing' approach for our arteries."

    Wednesday, 3 February 2010

    The super-pill that could help you live past 100

    reposted from:


    03/02/2010
    Daily Telegraph
    By: Presswatch
    "The super-pill that could help you live past 100"
    Scientists are on the verge of developing a pill that could help people live past 100, according to experts. The drug, which is designed to mimic the actions of three genes that aid longevity, could be ready for testing within three years. Two of the genes increase the production of so-called good cholesterol in the body, reducing the risk of heart disease and stroke, while the third helps to prevent diabetes. People with the gene variants are also 80 per cent less likely to develop Alzheimer's, studies indicate.

    Saturday, 19 December 2009

    'Full genetics of cancer mapped'

    Many newspapers have reported that scientists have "cracked the code" of cancer with the analysis of the entire genetic sequence of malignant melanoma skin cancer and an aggressive form of lung cancer.

    In the past, researchers were only able to look at smaller sections of DNA, as sequencing the entire DNA of a cell would have taken a very long time. Recent advances in technology have allowed the analysis of the entire sequence of DNA within a cell much more quickly.

    However, cancer is a complex disease and not all individuals with cancer will have exactly the same mutations found in this research. Equally, not all of the mutations identified will be contributing to the cancerous nature of the cells. Therefore, future research is needed to look at DNA from many other individuals to pinpoint which mutations are likely to cause these cancers.

    These types of advances may mean that, eventually, each patient will routinely have their entire cancer genome sequenced. However, this is not likely to happen in the near future and we do not yet know enough to be able to use this knowledge to help tailor indviduals’ treatments, as some newspapers have claimed.

    Where did the story come from?

    This research was conducted by Dr Erin D Pleasance and colleagues from Wellcome Trust Sanger Institute and other research centres in the UK and the US. It was published as two papers in the peer-reviewed scientific journal Nature. One study was funded by the Wellcome Trust, sources of funding were not stated for the other.

    These studies are part of a larger ongoing project called The International Cancer Genome Consortium that is attempting to genetically analyse 50 different tumour types.

    What kind of research was this?

    This was laboratory research looking at the genetic sequence of various human cancer cells grown in the laboratory. The researchers wanted to identify genetic mutations that might cause cancer.
    Previous studies have mostly looked at mutations in small numbers of genes or in small sections of DNA, but this research aimed to read the entire sequence genetic sequence of these cancerous cells. Advances in DNA technology have now made it possible to perform this type of analysis much more quickly and easily than before.
    The researchers hope that looking at the entire genetic sequence will help them to further understand factors such as how DNA is affected by known cancer risks such as UV rays and tobacco smoke, as well as which mutations might be behind the formation of cancers and how the cells attempt to repair mutated DNA.

    What did the research involve?

    The researchers used cancer cells that had been removed from people with cancer and grown in a laboratory. They looked at the overall pattern of mutations that the cancer cells contained. The cells examined were malignant melanoma cells taken from one person and small cell lung cancer cells (SCLC – a particularly aggressive form of lung cancer) taken from another person. The researchers also analysed the DNA of normal cells from these patients to help identify the mutations in the DNA of the cancerous cells.
    The SCLC cells came from a site where the lung cancer had metastasised (spread) to the bone of a 55-year-old man before he received chemotherapy. It was not known whether this man had smoked. The melanoma cells came from a metastasis in a 43-year-old man with malignant melanoma before he received chemotherapy.
    The researchers used special techniques that can rapidly read the sequence of letters that make up the code of the DNA in the cells, a technique called sequencing. Advances in DNA technology have made it easier and quicker to sequence the entire genetic code of a cell, called the genome.
    The researchers then compared the sequences in the cancer cells to those in normal cells to identify any changes (mutations) in their DNA. These changes can range from changing a single letter in the code to rearranging whole sections of DNA. They looked at the characteristics of these mutations to see whether they were typical of the effects of UV exposure (a known risk factor for skin cancer), or of the 60 chemicals that are found in tobacco smoke (a known risk factor for lung cancer) that might potentially cause mutations. They also looked at what genes (sequences which carry instructions for making proteins) were affected, and whether the mutations were spread evenly throughout the DNA.

    What were the basic results?

    In the malignant melanoma skin cancer cells, the researchers identified 33,345 single-letter changes in the DNA. The also identified various other mutations involving rearrangements, insertions and deletions of sections of DNA. Most of the mutations identified appeared to be caused by ultraviolet light exposure, which is known to be a risk factor for skin cancer. Mutations were found to be more common in areas where the genetic sequence did not contain any genes, suggesting that the cells’ DNA repair mechanisms had preferentially fixed mutations that affected genes.
    In the SCLC line, the researchers identified 22,910 single-letter changes in the DNA. This included 134 changes within the pieces of genes that contained the instructions for making proteins. These genes with mutations included those known to play a role in cancer. As was the case in the melanoma cells, they also identified larger mutations involving rearrangements, insertions and deletions of chunks of DNA.
    Most of the mutations they identified in the lung cancer cells did not appear to be giving them a ‘selective advantage’ that would help them to survive and divide. The mutations were of varying types, which indicated the effects of the many different cancer–causing chemicals found in cigarette smoke. Again, there was evidence that suggested that the cells’ DNA repair mechanisms had ‘fixed’ some of the mutations that affected genes.
    The researchers identified one specific mutation that caused a duplication of a part of a gene called CHD7. Two other SCLC lines were also shown to have mutations that caused part of the CHD7 gene to be inappropriately joined to the PVT1 gene. This suggested that rearrangements in the CHD7 gene may be common in small cell lung cancer.
    Based on their results and the average number of cigarettes needed to cause lung cancer, the researchers estimated that cells which eventually become cancerous, develop an average of one mutation for every 15 cigarettes smoked.

    How did the researchers interpret the results?

    The researchers concluded that their results “illustrate the power of a cancer genome sequence to reveal traces of the DNA damage, repair, mutation and selection processes that were operative years before the cancer became symptomatic”. They also say their findings “illustrate the potential for next-generation sequencing to provide unprecedented insights into mutational processes, cellular repair pathways and gene networks associated with cancer.”

    Conclusion

    This research has been made possible by advances in DNA sequencing technology, and understanding the mutations that lie behind cancer may have numerous implications for future research. However, cancer is a complex disease and not all of the mutations identified in these studies will be contributing to the cancerous nature of the cells. Equally, not all individuals with cancer will have exactly the same mutations. Therefore, future research will be needed to look at DNA from many other individuals to try to identify which mutations are likely to be causing the cancers.
    Eventually, these and future advances may mean that sequencing the entire genome of cancer cells from each individual may eventually become a routine part of cancer care. However, this is not likely to be the case in the near future and currently, we do not know enough to be able to use this knowledge to help doctors to tailor treatment to the individual.


    Links to the headlines

    Just 15 cigs can give you cancerDaily Mirror, December 17 2009
    Cancer ‘maps’ pave way for tailored drugsFinancial Times, December 17 2009
    Docs make Big C breakthroughThe Sun, December 17 2009

    Links to the science

    Pleasance ED, Keira Cheetham R, Stephens PJ. et al. A comprehensive catalogue of somatic mutations from a human cancer genomeNature [advance online publication] December 16 2009
    Pleasance ED, Stephens PJ, O’Meara S et al. A small-cell lung cancer genome with complex signatures of tobacco exposure.Nature [advance online publication] December 16 2009